IBI323
IBI323 is a PD-L1/LAG-3 dual inhibitory antibody with Kd values of 0.0132 nM and 0.671 nM, respectively. IBI323 blocks the interaction of PD-L1 with PD-1 and CD80, as well as the interaction of LAG-3 with MHC-II. IBI323 mediates cross-linking of PD-L1-positive and LAG-3-positive cells, enhances T cell activation and cytokine secretion, and increases tumor-specific T cells in tumors and blood. IBI323 has a LALA mutation that reduces Fc-mediated effector function and inhibits tumor growth in humanized mouse models. IBI323 can be used for research on melanoma and colon cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- 순도&문서
- References
-
Help & FAQs
Biological Activity
제품 설명
Species Reactivity
Human
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
39.75 nM
|
Blocking of LAG-3/MHC-II interaction in CHO cells overexpressing human MHC class II assessed by FACS after 30 min incubation at 4°C.
Blocking of LAG-3/MHC-II interaction in CHO cells overexpressing human MHC class II assessed by FACS after 30 min incubation at 4°C.
|
34239776 |
In Vitro
IBI323 (incubated at 4°C for 30 min) binds activated primary human CD4+ T cells in a dose-dependent manner[1].
IBI323 (incubated at 4°C for 30 min) blocks PD-L1/PD-1 and PD-L1/CD80 interactions on CHO-S-hPD-L1 cells, with IC50 values of 23.99 nM and 14.96 nM, respectively[1].
IBI323 (incubated at 4°C for 30 min) blocks the LAG-3/MHC-II interaction with an IC50 of 39.75 nM[1].
IBI323 (6 h) activates LAG-3/MHC-II reporter Jurkat cells by blocking the LAG-3/MHC-II interaction[1].
IBI323 (incubated at 4°C for 30 min to room temperature for 1 h) mediates bridging between PD-L1+ MDA-MB-231 cells and LAG-3+ Jurkat T cells[1].
IBI323 (200 nM; 4 days) enhances IFN-γ and IL-2 secretion in a dose-dependent manner in human DC/CD4+ T cell mixed leukocyte reaction[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
IBI323 (3.5-11.6 mg/kg; intraperitoneal injection; on days 1, 7, 10, 13, and 16 after tumor cell implantation) significantly inhibited the growth of A375 melanoma in humanized NOG mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6-CD274tm1(hCD274)LAG3tm1(hLAG3) (female)[1]
-
Dosage:5.8 mg/kg; 1 mg/kg
-
Administration:i.p. on days 6, 10, 14, 17, and 21 post implantation
-
Result:Inhibited tumor growth in a dose-dependent manner.
Showed a significant reduction in tumor volume relative to the IgG group.
-
Animal Model:NOG (strain: 408; female)[1]
-
Dosage:3.5 mg/kg; 11.6 mg/kg
-
Administration:i.p. on days 1, 7, 10, 13, and 16 after tumor cell implantation
-
Result:Significantly inhibited A375 tumor growth at both 3.5 mg/kg and 11.6 mg/kg doses.
Target
LAG-3 & PD-L1
Conjugated
Unconjugated
신청
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[IBI323]
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
IBI323 Related Classifications
HY-P992546 Related Classifications
Powered by Bioz